|
Ciprofibrate 100mg Tablets
Drug description :
Each tablet contains 100mg ciprofibrate as the active ingredient.
Presentation :
Tablet. White to off white capsule shaped tablets with a breakline
on one side and embossed 'S170' on the other
Indications :
Ciprofibrate 100mg tablets are recommended for the treatment of
primary dyslipoproteinaemias, including types IIa, IIb, III and IV
(hypercholesterolaemia, hypertriglyceridaemia and combined forms)
- refractory to appropriate dietary treatment.
Dietary measures should be continued during therapy.
Adult Dosage :
Adults
The recommended dosage is one tablet (100mg ciprofibrate) per day.
This dose should not be exceeded (see Precautions).
Use in Case of Impaired Renal Function
In moderate renal impairment it is recommended that dosage be
reduced to one tablet every other day. Patients should be
carefully monitored. Ciprofibrate 100mg tablets should not be used
in severe renal impairment.
Child Dosage :
Use in Children
Not recommended since safety and efficacy in children has not been
established.
Ciprofibrate 100mg tablets are for oral administration only
Elderly Dosage :
Elderly Patients
As for adults, but see Precautions and Warnings.
Contra Indications :
Severe hepatic impairment.
Severe renal impairment.
Pregnancy and lactation.
Concurrent use with another fibrate.
Hypersensitivity to the active substance or to any component of
the product.
Interactions :
* Contra-indicated combination
Other fibrates: As with other fibrates, the risk of rhabdomyolysis
and myoglobinuria may be increased if ciprofibrate is used in
combination with other fibrates.
* Not recommended combinations
HMG CoA reductase inhibitors: As with other fibrates, the risk of
myopathy, rhabdomyolysis and myoglobinuria may be increased if
ciprofibrate is used in combination with HMG CoA reductase
inhibitors. The benefits of combined use should be carefully
weighed against the risks. Physicians contemplating concomitant
therapy with HMG CoA reductase inhibitors should consult the of
the relevant HMG CoA reductase inhibitor as some higher doses are
contraindicated / not recommended with fibrates.
* Combination requiring caution
Oral anticoagulant therapy: Ciprofibrate is highly protein bound
and therefore likely to displace other drugs from plasma protein
binding sites. Ciprofibrate has been shown to potentiate the
effect of warfarin, indicating that concomitant oral anticoagulant
therapy should be given at reduced dosage and adjusted according
to INR.
* Combination to be taken into account
Oral hypoglycaemics: A possible interaction should be considered.
|
Quality
